Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch
Filed in archive Treatment by Gloria Gamat on May 10, 2007

A product of Schwarz Bioscience (U.S. subsidiary of Schwarz Pharma AG), Neupro works by delivering the drug rotigotine (a dopamine agonist) continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours.
[A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine.]
Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease - belongs to a group of conditions called motor system disorders that is a result of the loss of dopamine-producing brain cells.
Read the full report from Schwarz Pharma and FDA.
Permalink: Neupro® (rotigotine transdermal system): First FDA-Approved Parkinson's Disease Patch
Tags:
Parkinsons disease patch
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/68463

















